1. Home
  2. TASK vs LYEL Comparison

TASK vs LYEL Comparison

Compare TASK & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TaskUs Inc.

TASK

TaskUs Inc.

HOLD

Current Price

$6.31

Market Cap

585.9M

Sector

Technology

ML Signal

HOLD

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$20.45

Market Cap

556.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TASK
LYEL
Founded
2008
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
585.9M
556.1M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
TASK
LYEL
Price
$6.31
$20.45
Analyst Decision
Hold
Strong Buy
Analyst Count
5
5
Target Price
$14.70
$30.60
AVG Volume (30 Days)
537.6K
78.2K
Earning Date
05-06-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
120.00
N/A
EPS
1.10
N/A
Revenue
N/A
$36,000.00
Revenue This Year
$5.95
N/A
Revenue Next Year
$6.46
$8,712.13
P/E Ratio
$5.78
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.20
$0.39
52 Week High
$18.39
$45.00

Technical Indicators

Market Signals
Indicator
TASK
LYEL
Relative Strength Index (RSI) 32.48 40.69
Support Level $6.30 $16.20
Resistance Level $7.54 $26.89
Average True Range (ATR) 0.32 1.61
MACD 0.06 -0.29
Stochastic Oscillator 3.12 3.79

Price Performance

Historical Comparison
TASK
LYEL

About TASK TaskUs Inc.

TaskUs Inc provides outsourced digital services. Its service offerings include Digital Customer Experience consists of omnichannel customer care services, delivered through digital (non-voice) channels, also including learning experience and sales and customer acquisition services; Trust & Safety consists of monitoring, reviewing and managing user and advertiser-generated content on online platforms to ensure it complies with community guidelines, legal regulations and platform specific policies; and AI Services consists of large language model support and high-quality data labeling services, annotation, context relevance and transcription services performed for the purpose of training and tuning machine learning algorithms, enabling them to develop cutting-edge AI systems.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: